You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Xeljanz

Showing 1 - 25 of 68
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Juvenile Idiopathic Arthritis

Not yet recruiting
  • Psoriatic Arthritis, Juvenile
  • Polyarticular Juvenile Idiopathic Arthritis
  • Xeljanz
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 22, 2023

Xeljanz Special Investigation for Long-term Use in UC Patients

Completed
  • Ulcerative Colitis
    • Tokyo, Japan
      Pfizer Local Country Office
    Dec 13, 2022

    Korean Post-marketing Surveillance for Xeljanz XR

    Recruiting
    • Active Moderate to Severe Rheumatoid Arthritis
    • Active Ankylosing Spondylitis
    • Tofacitinib XR
    • Seoul, Korea, Republic of
      Pfizer
    Oct 10, 2022

    Xeljanz (Registered) in Ulcerative Colitis Patients

    Completed
    • Ulcerative Colitis
    • Non-intervention
    • Seoul, Korea, Republic of
      Pfizer
    Nov 16, 2022

    Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis Trial in Portland (drug, diagnostic test, genetic)

    Completed
    Has Results
    • Sarcoidosis, Pulmonary
    • +2 more
    • Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial
    • +5 more
    • Portland, Oregon
      Oregon Health & Science University
    Dec 3, 2021

    Tofacitinib Special Investigation for Rheumatoid Arthritis

    Completed
    • Rheumatoid Arthritis
    • Tofacitinib (Xeljanz)
    • Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc
    • Tokyo, Japan
      (unnamed)
    Sep 27, 2021

    Aneurysm, Behcet Syndrome, Vascular Type Trial in Beijing (tocilizumab, tofacitinib, cyclophosphamide)

    Not yet recruiting
    • Aneurysm
    • Behcet Syndrome, Vascular Type
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Apr 26, 2023

    Down Syndrome, Regression Trial (Lorazepam, Intravenous immunoglobulin (IVIG), Tofacitinib)

    Not yet recruiting
    • Down Syndrome
    • Regression
    • (no location specified)
    Dec 14, 2022

    Rheumatoid Arthritis Trial in Matsumoto (The effectiveness of Xeljanz in rheumatoid arthritis patients)

    Recruiting
    • Rheumatoid Arthritis
    • The effectiveness of Xeljanz in rheumatoid arthritis patients
    • Matsumoto, Nagano, Japan
      Yukio Nakamura
    Sep 20, 2021

    Ulcerative Colitis Trial in Los Angeles (Vedolizumab, Tofacitinib)

    Not yet recruiting
    • Ulcerative Colitis
    • Los Angeles, California
      Cedars Sinai Medical Center
    Oct 18, 2023

    Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema Trial in Aurora (Tofacitinib)

    Recruiting
    • Down Syndrome
    • +5 more
    • Aurora, Colorado
      Linda Crnic Institute for Down Syndrome
    Jan 17, 2023

    Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease Trial run by the NIAID (XELJANZ

    Enrolling by invitation
    • Chronic Granulomatous Disease
    • +3 more
    • XELJANZ (tofacitinib)
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 19, 2023

    Rheumatoid Arthritis Trial in London (Etanercept, tofacitinib)

    Recruiting
    • Rheumatoid Arthritis
    • London, Ontario, Canada
      Rheumatology Clinic, St. Joseph's Health Care
    May 10, 2022

    Cutaneous Lupus, Systemic Lupus Erythematosus Trial in Cincinnati, Cleveland (Tofacitinib)

    Completed
    • Cutaneous Lupus
    • Systemic Lupus Erythematosus
    • Cincinnati, Ohio
    • +1 more
    Dec 19, 2022

    Among Patients Treated With Xeljanz vs Biologics

    Completed
    Has Results
    • Arthritis, Rheumatoid
      • New York, New York
        Pfizer
      May 12, 2021

      Alopecia Areata Trial in Bangkok (Tofacitinib)

      Completed
      Has Results
      • Alopecia Areata
      • Bangkok, Thailand
        Institute of Dermatology
      Mar 28, 2022

      Systemic Lupus Erythematosus, Cutaneous Lupus Trial in Ann Arbor (Tofacitinib)

      Recruiting
      • Systemic Lupus Erythematosus
      • Cutaneous Lupus
      • Ann Arbor, Michigan
        University of Michigan Health System: Department of Internal Med
      May 2, 2022

      Psoriatic Arthritis, Spondylitis, Sacroilitis Trial in Germany (Tofacitinib 5 MG Oral Tablet [Xeljanz], Placebo oral tablet)

      Recruiting
      • Psoriatic Arthritis
      • +2 more
      • Tofacitinib 5 MG Oral Tablet [Xeljanz]
      • Placebo oral tablet
      • Berlin-Steglitz, Germany
      • +18 more
      Jul 23, 2022

      Psoriatic Arthritis, Withdrawal, Reduction Trial in Erlangen (Prednisolone, Sulfasalazine, Leflunomide)

      Recruiting
      • Psoriatic Arthritis
      • +2 more
      • Erlangen, Bavaria, Germany
        Universitätsklinikum Erlangen
      Nov 10, 2022

      Discoid Lupus Erythematosus, Systemic Lupus Erythematosus Trial in Boston (Tofacitinib citrate)

      Terminated
      • Discoid Lupus Erythematosus
      • Systemic Lupus Erythematosus
      • Tofacitinib citrate
      • Boston, Massachusetts
        Tufts Medical Center
      Jan 6, 2022

      Healthy Subjects Trial in Québec (Tofacitinib Citrate)

      Completed
      • Healthy Subjects
      • Tofacitinib Citrate
      • Québec, Canada
        Syneos Health Facility
      Nov 25, 2021

      Rheumatoid Arthritis Trial in Matsumoto ("Baricitinib", "olumiant®", "Biologics", Tofacitinib 5 MG [Xeljanz])

      Recruiting
      • Rheumatoid Arthritis
      • "Baricitinib", "olumiant®"
      • +2 more
      • Matsumoto, Nagano, Japan
        Yukio Nakamura
      Sep 20, 2021

      Healthy Trial in Merksem (Tofacitinib)

      Completed
      • Healthy
      • Merksem, Belgium
        Clinical Pharmacology Unit
      Oct 26, 2021

      Rheumatoid Arthritis Trial (GS-5718, Placebo to match GS-5718, Tofacitinib 5 mg)

      Withdrawn
      • Rheumatoid Arthritis
      • (no location specified)
      May 11, 2022

      Tumors With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic Trial run by the NCI (LMB-100,

      Active, not recruiting
      Has Results
      • Neoplasms With Mesothelin Expression
      • +3 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 18, 2022